<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39438911</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>2925</StartPage><MedlinePgn>2925</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2925</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-024-20364-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic search of PubMed, Scopus, and ProQuest from December 2019 to January 2023. After critical appraisal and quality assessment, a qualitative synthesis of the identified relevant articles was performed. The random-effects model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger's test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I<sup>2</sup> statistics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 70 peer-reviewed articles were selected that together included 2,454,192 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.3% (95% CI: 4.6 - 18.0%, n = 70). The highest seroprevalence was observed in Asia (17.7%), followed by Africa (16.1%). The seroprevalence in studies conducted before the introduction of the vaccine was 6.1%, whereas those of studies conducted after vaccines were available was 27.6%. High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (15.2%), while lower (12.5%) in those that measured antibodies against the N protein. A high seroprevalence was observed in studies that only measured IgG antibodies (16.3%), and it was 5.9% in studies that measured total antibodies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The prevalence of SARS-CoV-2 antibodies among healthy blood donors varies, potentially indicating geographical disparities in transmission and vaccination rates. To enhance community resilience, addressing these differences through inclusive health policies and adaptable public health measures is crucial.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ukwishaka</LastName><ForeName>Joyeuse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rwanda Biomedical Center, Maternal Child and Community Health Division, Kigali, Rwanda. joyukwishaka@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jhpiego, Kigali, Rwanda. joyukwishaka@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles, Brussels, Belgium. joyukwishaka@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mela</LastName><ForeName>Cyril Fotabong</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aseneh</LastName><ForeName>Jerry Brown Njoh</ForeName><Initials>JBN</Initials><AffiliationInfo><Affiliation>Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ettaj</LastName><ForeName>Malak</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anthropology, University of California-Davis, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilboudo</LastName><ForeName>Dieudonné</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danwang</LastName><ForeName>Celestin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinton Health Access Initiative, Inc, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samadoulougou</LastName><ForeName>Sekou</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Evaluation Platform on Obesity Prevention, Quebec Heart and Lung Institute, Quebec, QC, G1V 4G5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Research on Planning and Development, Université Laval, Quebec, QC, G1V 0A6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirakoya-Samadoulougou</LastName><ForeName>Fati</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001782" MajorTopicYN="Y">Blood Donors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody</Keyword><Keyword MajorTopicYN="N">Blood donors</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Seroprevalence</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438911</ArticleId><ArticleId IdType="doi">10.1186/s12889-024-20364-5</ArticleId><ArticleId IdType="pii">10.1186/s12889-024-20364-5</ArticleId><ArticleId IdType="pmc">PMC11515703</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . Cited 2023 May 30 .</Citation></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: a meta-analysis. J Med Virol. 2020;92(10):1902–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262119</ArticleId><ArticleId IdType="pubmed">32293716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Network Open. American Medical Association; 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-june-2022. Cited 2023 May 30.</Citation></Reference><Reference><Citation>WHO. Coronavirus disease (COVID-19) pandemic. 2023. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey={adgroupsurvey}&amp;gclid=CjwKCAjwvdajBhBEEiwAeMh1U3YEJgp_i4kDbru_PewKkuzO4UJvcIq9sz220T5Qnh549pPxlGpVKBoCW4sQAvD_BwE. Cited 2023 May 30 .</Citation></Reference><Reference><Citation>WHO. Listings of WHO’s response to COVID-19. 2020. Available from: https://www.who.int/news/item/29-06-2020-covidtimeline . Cited 2023 May 30 .</Citation></Reference><Reference><Citation>Soriano JB, Villagrasa JR, Ancochea J. COVID-19 in youth and the fifth wave. Arch Bronconeumol. 2022;58:213–4 Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8438794</ArticleId><ArticleId IdType="pubmed">34539032</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Vaccine efficacy, effectiveness and protection. 2021. Available from: https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection . Cited 2023 May 30 .</Citation></Reference><Reference><Citation>WHO. Covid-19 epidemiological update on COVID-19 – 17 May 2024. Available from https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-167. Cited 2024 June 06.</Citation></Reference><Reference><Citation>WHO. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. 2023. Available from: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic . Cited 2023 May 30 .</Citation></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, et al. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep. 2020;10(1):20048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674414</ArticleId><ArticleId IdType="pubmed">33208819</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. 2022;28(5):1042–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9117133</ArticleId><ArticleId IdType="pubmed">35241844</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Interim guidelines for COVID-19 antibody testing. 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing/antibody-tests-guidelines.html . Cited 2023 May 30 .</Citation></Reference><Reference><Citation>Celikgil A, Massimi AB, Nakouzi A, Herrera NG, Morano NC, Lee JH, et al. SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients. PLoS One. 2023;18(2 February):e0276829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9910743</ArticleId><ArticleId IdType="pubmed">36757919</ArticleId></ArticleIdList></Reference><Reference><Citation>Guevara-Hoyer K, Fuentes-Antrás J, De la Fuente-Muñoz E, de la Peña AR, Viñuela M, Cabello-Clotet N, et al. Serological tests in the detection of SARS-CoV-2 antibodies. Diagnostics. 2021;11(4):678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8069538</ArticleId><ArticleId IdType="pubmed">33918840</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020;222:206–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313936</ArticleId><ArticleId IdType="pubmed">32427334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff F, Dahma H, Duterme C, Van den Wijngaert S, Vandenberg O, Cotton F, et al. Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays. Diagn Microbiol Infect Dis. 2020;98(3):115140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7354376</ArticleId><ArticleId IdType="pubmed">32829098</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Coronavirus disease (COVID-19): herd immunity, lockdowns and COVID-19. 2020.</Citation></Reference><Reference><Citation>WHO. Public health surveillance for COVID-19: interim guidance. 2022. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-SurveillanceGuidance-2022.2 . Cited 2023 May 30 .</Citation></Reference><Reference><Citation>Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China — key questions for impact assessment. N Engl J Med. 2020;382(8):692–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">31978293</ArticleId></ArticleIdList></Reference><Reference><Citation>Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289564</ArticleId><ArticleId IdType="pubmed">32534626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra T, Agarwal D, Himanshu D, Agarwal M, Puri B. SARS-CoV-2 IgG surveillance in asymptomatic blood donors and health workers. Adv Med. 2021;29(2021):1–6.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6.</Citation></Reference><Reference><Citation>NHI. Study quality assessment tools. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Cited 2022 Dec 11.</Citation></Reference><Reference><Citation>Chen Y, Chen D, Wang Y, Han Y. Using freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Aesthetic Plast Surg. 2023;47:83–4 Springer.</Citation><ArticleIdList><ArticleId IdType="pubmed">35764810</ArticleId></ArticleIdList></Reference><Reference><Citation>Azami M, Moradi Y, Moradkhani A, Aghaei A. SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis. Eur J Med Res. 2022;27:81 BioMed Central Ltd.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9160514</ArticleId><ArticleId IdType="pubmed">35655237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Glob Health. 2022;7:e008793 BMJ Publishing Group.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9402450</ArticleId><ArticleId IdType="pubmed">35998978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies. PLoS Med. 2022;19(11).</Citation></Reference><Reference><Citation>Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and metaanalysis. PLoS One. 2021;16(6):1–21.</Citation></Reference><Reference><Citation>Naeimi R, Sepidarkish M, Mollalo A, Parsa H, Mahjour S, Safarpour F, et al. SARS-CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis. EClinicalMedicine. 2023;1:56.</Citation></Reference><Reference><Citation>Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021;108:120–34 W.B. Saunders Ltd.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668234</ArticleId><ArticleId IdType="pubmed">33212126</ArticleId></ArticleIdList></Reference><Reference><Citation>Nourmohammadi H, Dehkordi AH, Adibi A, Amin Hashemipour SM, Abdan M, Fakhri M, et al. Seroprevalence of COVID-19 in Blood Donors: A Systematic Review and Meta-Analysis. Adv Virol. 2022;2022:1–10. </Citation></Reference><Reference><Citation>Briz-Redón Á, Serrano-Aroca Á. The effect of climate on the spread of the COVID-19 pandemic: A review of findings, and statistical and modelling techniques. Prog Phys Geogr. 2020;44(5):591–604. </Citation></Reference><Reference><Citation>Ukwishaka J, Ndayishimiye Y, Destine E, Danwang C, Kirakoya-Samadoulougou F. Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis. BMC Public Health. 2023;23(1). Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-023-15626-7#. Cited 2023 May 24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-023-15626-7#</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022;209:112911 Academic Press Inc.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824301</ArticleId><ArticleId IdType="pubmed">35149106</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021;385(24):e83. </Citation></Reference><Reference><Citation>Chemaitelly H, Bertollin R, Abu-Raddad LJ. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N Engl J Med. 2021;385(27):2582–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693687</ArticleId><ArticleId IdType="pubmed">34879193</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609604</ArticleId><ArticleId IdType="pubmed">34706170</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. 2021;385(26):2413–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728797</ArticleId><ArticleId IdType="pubmed">34879190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393–400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N Engl J Med. 2022;386(23):2201–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul A Kristiansen MPVBGMPDKMSPIK. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397:1347–8.</Citation></Reference><Reference><Citation>Perkmann T, Mucher P, Ösze D, Müller A, Perkmann-Nagele N, Koller T, et al. Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology. J Clin Virol. 2023;1:158.</Citation></Reference><Reference><Citation>Brochot E, Demey B, Handala L, François C, Duverlie G, Castelain S. Comparison of different serological assays for SARS-CoV-2 in real life. J Clin Virol. 2020;1:130.</Citation></Reference><Reference><Citation>Kundu D, Gautam P, Dayanand D, Gunasekaran K, Manesh A, Sebastian M, et al. The role and diagnostic accuracy of serology for COVID-19. BMC Infect Dis. 2022;22(1):390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017961</ArticleId><ArticleId IdType="pubmed">35439957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Li Z, Whelan MG, Kim D, Cao C, Yanes-Lane M, et al. Serology assays used in SARS-CoV-2 Seroprevalence surveys worldwide: a systematic review and meta-analysis of assay features, testing algorithms, and performance. Vaccines (Basel). 2022;10(12):2000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9783516</ArticleId><ArticleId IdType="pubmed">36560415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;1:370.</Citation></Reference><Reference><Citation>Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;1(102):577–83.</Citation></Reference><Reference><Citation>Emmerich P, Murawski C, Ehmen C, von Possel R, Pekarek N, Oestereich L, et al. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. Trop Med Int Health. 2021;26(6):621–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014856</ArticleId><ArticleId IdType="pubmed">33666297</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin N, Murray L, Ozynski B, Richards GA, Paget G, Venturas J, et al. Age significantly influences the sensitivity of SARS-CoV-2 rapid antibody assays. Int J Infect Dis. 2021;1(109):304–9.</Citation></Reference><Reference><Citation>Bottomley C, Otiende M, Uyoga S, Gallagher K, Kagucia EW, Etyang AO, et al. Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels. Nat Commun. 2021;12(1):6196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548402</ArticleId><ArticleId IdType="pubmed">34702829</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Okazaki K, Kitai Y, Shinohara K, Yukawa S, Noguchi T, et al. Comparison of six antibody assays and two combination assays for COVID-19. Virol J. 2022;19(1):24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8811998</ArticleId><ArticleId IdType="pubmed">35115008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>